<p>根據公司在最近向美國證券交易委員會（SEC）披露的信息，Donald L. Hagan LLC 在第三季度購買了 Bristol Myers Squibb Company（紐約證券交易所代碼：BMY - 免費報告）的新股份。該基金購買了 20,550 股生物製藥公司的股票，價值約為 927,000 美元。</p>
<ul>
<li>為什麼 GRAIL 股票可能成為生物科技的下一個重大突破</li>
</ul>
<p>其他大型投資者最近也對該公司的持股進行了調整。Brighton Jones LLC 在第四季度將其在 Bristol Myers Squibb 的股份增加了 33.4%。Brighton Jones LLC 現在擁有 19,728 股生物製藥公司的股票，價值為 1,116,000 美元，此前在上個季度又購買了 4,935 股。Jump Financial LLC 在第一季度購買了 Bristol Myers Squibb 的新股份，價值約為 438,000 美元。Ieq Capital LLC 在第一季度將其在 Bristol Myers Squibb 的持股增加了 27.6%。Ieq Capital LLC 現在擁有 172,523 股生物製藥公司的股票，價值為 10,522,000 美元，此前在上個季度又購買了 37,362 股。CreativeOne Wealth LLC 在第一季度將其在 Bristol Myers Squibb 的股份提高了 6.4%。CreativeOne Wealth LLC 現在擁有 32,748 股生物製藥公司的股票，價值為 1,997,000 美元，此前在此期間又購買了 1,969 股。最後，Transamerica Financial Advisors LLC 在第一季度將其在 Bristol Myers Squibb 的持股提高了 1.0%。Transamerica Financial Advisors LLC 現在擁有 24,065 股生物製藥公司的股票，價值為 1,468,000 美元，此前在上個季度又購買了 241 股。機構投資者和對沖基金持有該公司 76.41% 的股份。</p>
<p>獲取 <strong>Bristol Myers Squibb</strong> 的提醒：</p>
<h2>Bristol Myers Squibb 股票表現</h2>
<p>紐約證券交易所 BMY 週五開盤價為 54.63 美元。該公司的 50 日移動平均價格為 48.61 美元，200 日移動平均價格為 47.33 美元。Bristol Myers Squibb Company 的 12 個月低點為 42.52 美元，12 個月高點為 63.33 美元。該公司的市值為 1,112 億美元，市盈率為 18.45，市盈增長比率為 8.37，貝塔係數為 0.29。該公司的速動比率為 1.17，流動比率為 1.27，債務與股本比率為 2.39。</p>
<ul>
<li>不要被反彈所迷惑：市場風暴尚未結束</li>
</ul>
<p>Bristol Myers Squibb（紐約證券交易所代碼：BMY - 獲取免費報告）最近一次公佈財報是在 10 月 30 日，週四。該生物製藥公司報告本季度每股收益為 1.63 美元，超出市場共識預期的 1.52 美元，超出幅度為 0.11 美元。該公司本季度的收入為 122.2 億美元，而分析師預期為 117.5 億美元。Bristol Myers Squibb 的淨利潤率為 12.57%，股本回報率為 76.53%。該公司本季度的收入同比增長了 2.8%。去年同期，該公司每股收益為 1.80 美元。Bristol Myers Squibb 已將其 2025 財年的指導目標設定為每股收益 6.400-6.600 美元。分析師預計 Bristol Myers Squibb Company 在當前年度將發佈每股收益 6.74 美元。</p>
<h2>Bristol Myers Squibb 增加股息</h2>
<p>該公司還最近宣佈了一項季度股息，將於 2 月 2 日（星期一）支付。1 月 2 日（星期五）登記的股東將獲得每股 0.63 美元的股息。這相當於每年 2.52 美元的股息和 4.6% 的股息收益率。除息日期為 1 月 2 日（星期五）。這比 Bristol Myers Squibb 之前的季度股息 0.62 美元有所增加。Bristol Myers Squibb 的股息支付比率目前為 83.78%。</p>
<h2>分析師設定新的價格目標</h2>
<ul>
<li>MarketBeat 週迴顧 – 02/03 - 02/07</li>
</ul>
<p>一些研究分析師最近對該公司發表了看法。Sanford C. Bernstein 在 11 月 3 日（星期一）的一份報告中重申了對 Bristol Myers Squibb 股票的 “市場表現” 評級。華爾街 Zen 在 11 月 8 日（星期六）的一份報告中將 Bristol Myers Squibb 的股票評級從 “買入” 上調至 “強力買入”。Guggenheim 在週二的一份研究報告中重申了對 Bristol Myers Squibb 股票的 “買入” 評級。Weiss Ratings 在 10 月 14 日（星期二）的一份報告中重申了對 Bristol Myers Squibb 股票的 “持有（C-）” 評級。最後，BMO Capital Markets 在 11 月 17 日（星期一）的一份報告中重申了對 Bristol Myers Squibb 股票的 “市場表現” 評級。六位股票研究分析師對該股票給予了買入評級，十四位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com，該公司目前的平均評級為 “持有”，平均目標價格為 54.62 美元。</p>
<p><strong>閲讀我們關於 Bristol Myers Squibb 的最新股票報告</strong></p>
<h2>Bristol Myers Squibb 公司簡介</h2>
<p>（免費報告）</p>
<p>Bristol Myers Squibb 是一家全球生物製藥公司，總部位於新澤西州普林斯頓，專注於發現、開發和提供針對嚴重疾病的藥物。該公司的核心業務包括研究與開發、臨牀開發、製造和商業化多種治療領域的處方藥。BMS 專注於通過小分子和生物製劑推進腫瘤學、血液學、免疫學、心血管疾病和特殊領域的治療。</p>
<p>BMS 的市場產品組合和後期管線反映了對癌症和免疫介導疾病的強烈關注。</p>
<h2>精選故事</h2>
<ul>
<li>五隻我們更看好的股票超過 Bristol Myers Squibb</li>
<li>將你的 “死錢” 轉變為每月 306 美元以上（從這個月開始）</li>
<li>華盛頓準備戰爭</li>
<li>在 1 月 1 日之前將 1,000 美元投入這隻股票【不是 NVDA】</li>
<li>麥當勞的秘密</li>
<li>來自奇怪的新 “AI 燃料” 的 33,000% 繁榮？</li>
</ul>
<p><strong>想看看其他對沖基金持有的 BMY 股票嗎？</strong> 訪問 HoldingsChannel.com 獲取 Bristol Myers Squibb Company（紐約證券交易所代碼：BMY - 免費報告）的最新 13F 文件和內部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UCNlN5bWJvbD1CTVk?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UCNlN5bWJvbD1CTVk"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1000 美元在百時美施貴寶嗎？</h2>
<p>在考慮百時美施貴寶之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而百時美施貴寶並不在名單上。</p>
<p>雖然百時美施貴寶目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

百時美施貴寶

<p>Donald L. Hagan LLC 在第三季度收購了 20,550 股百時美施貴寶，價值約 927,000 美元。其他投資者，包括 Brighton Jones LLC 和 Ieq Capital LLC 也調整了他們在該公司的持倉。百時美施貴寶報告的季度每股收益為 1.63 美元，超出預期，並宣佈每股股息增加至 0.63 美元。分析師對該股票的評級不一，平均評級為 “持有”，目標價格為 54.62 美元</p>

<p>Donald L. Hagan LLC purchased a new position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 20,550 shares of the biopharmaceutical company's stock, valued at approximately $927,000.</p>
<div class="lb-trans"><p>根據公司在最近向美國證券交易委員會（SEC）披露的信息，Donald L. Hagan LLC 在第三季度購買了 Bristol Myers Squibb Company（紐約證券交易所代碼：BMY - 免費報告）的新股份。該基金購買了 20,550 股生物製藥公司的股票，價值約為 927,000 美元。</p>
</div><ul>
<li>Why GRAIL Stock Could Be Biotech’s Next Big Breakout</li>
</ul>
<div class="lb-trans"><ul>
<li>為什麼 GRAIL 股票可能成為生物科技的下一個重大突破</li>
</ul>
</div><p>Other large investors also recently made changes to their positions in the company. Brighton Jones LLC increased its stake in shares of Bristol Myers Squibb by 33.4% during the 4th quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company's stock worth $1,116,000 after purchasing an additional 4,935 shares during the last quarter. Jump Financial LLC bought a new position in Bristol Myers Squibb during the first quarter worth about $438,000. Ieq Capital LLC increased its position in Bristol Myers Squibb by 27.6% during the first quarter. Ieq Capital LLC now owns 172,523 shares of the biopharmaceutical company's stock worth $10,522,000 after buying an additional 37,362 shares during the last quarter. CreativeOne Wealth LLC raised its stake in Bristol Myers Squibb by 6.4% in the first quarter. CreativeOne Wealth LLC now owns 32,748 shares of the biopharmaceutical company's stock valued at $1,997,000 after buying an additional 1,969 shares during the period. Finally, Transamerica Financial Advisors LLC lifted its position in shares of Bristol Myers Squibb by 1.0% in the first quarter. Transamerica Financial Advisors LLC now owns 24,065 shares of the biopharmaceutical company's stock valued at $1,468,000 after buying an additional 241 shares during the last quarter. Institutional investors and hedge funds own 76.41% of the company's stock.</p>
<div class="lb-trans"><p>其他大型投資者最近也對該公司的持股進行了調整。Brighton Jones LLC 在第四季度將其在 Bristol Myers Squibb 的股份增加了 33.4%。Brighton Jones LLC 現在擁有 19,728 股生物製藥公司的股票，價值為 1,116,000 美元，此前在上個季度又購買了 4,935 股。Jump Financial LLC 在第一季度購買了 Bristol Myers Squibb 的新股份，價值約為 438,000 美元。Ieq Capital LLC 在第一季度將其在 Bristol Myers Squibb 的持股增加了 27.6%。Ieq Capital LLC 現在擁有 172,523 股生物製藥公司的股票，價值為 10,522,000 美元，此前在上個季度又購買了 37,362 股。CreativeOne Wealth LLC 在第一季度將其在 Bristol Myers Squibb 的股份提高了 6.4%。CreativeOne Wealth LLC 現在擁有 32,748 股生物製藥公司的股票，價值為 1,997,000 美元，此前在此期間又購買了 1,969 股。最後，Transamerica Financial Advisors LLC 在第一季度將其在 Bristol Myers Squibb 的持股提高了 1.0%。Transamerica Financial Advisors LLC 現在擁有 24,065 股生物製藥公司的股票，價值為 1,468,000 美元，此前在上個季度又購買了 241 股。機構投資者和對沖基金持有該公司 76.41% 的股份。</p>
</div><p>Get <strong>Bristol Myers Squibb</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Bristol Myers Squibb</strong> 的提醒：</p>
</div><h2>Bristol Myers Squibb Stock Performance</h2>
<div class="lb-trans"><h2>Bristol Myers Squibb 股票表現</h2>
</div><p>NYSE BMY opened at $54.63 on Friday. The firm has a 50-day moving average price of $48.61 and a two-hundred day moving average price of $47.33. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $63.33. The company has a market capitalization of $111.20 billion, a P/E ratio of 18.45, a P/E/G ratio of 8.37 and a beta of 0.29. The company has a quick ratio of 1.17, a current ratio of 1.27 and a debt-to-equity ratio of 2.39.</p>
<div class="lb-trans"><p>紐約證券交易所 BMY 週五開盤價為 54.63 美元。該公司的 50 日移動平均價格為 48.61 美元，200 日移動平均價格為 47.33 美元。Bristol Myers Squibb Company 的 12 個月低點為 42.52 美元，12 個月高點為 63.33 美元。該公司的市值為 1,112 億美元，市盈率為 18.45，市盈增長比率為 8.37，貝塔係數為 0.29。該公司的速動比率為 1.17，流動比率為 1.27，債務與股本比率為 2.39。</p>
</div><ul>
<li>Don’t Be Fooled by the Bounce: The Market Storm Isn’t Over Yet</li>
</ul>
<div class="lb-trans"><ul>
<li>不要被反彈所迷惑：市場風暴尚未結束</li>
</ul>
</div><p>Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 EPS for the quarter, topping the consensus estimate of $1.52 by $0.11. The company had revenue of $12.22 billion for the quarter, compared to analysts' expectations of $11.75 billion. Bristol Myers Squibb had a net margin of 12.57% and a return on equity of 76.53%. The business's revenue for the quarter was up 2.8% on a year-over-year basis. During the same period last year, the firm earned $1.80 earnings per share. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. Analysts anticipate that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.</p>
<div class="lb-trans"><p>Bristol Myers Squibb（紐約證券交易所代碼：BMY - 獲取免費報告）最近一次公佈財報是在 10 月 30 日，週四。該生物製藥公司報告本季度每股收益為 1.63 美元，超出市場共識預期的 1.52 美元，超出幅度為 0.11 美元。該公司本季度的收入為 122.2 億美元，而分析師預期為 117.5 億美元。Bristol Myers Squibb 的淨利潤率為 12.57%，股本回報率為 76.53%。該公司本季度的收入同比增長了 2.8%。去年同期，該公司每股收益為 1.80 美元。Bristol Myers Squibb 已將其 2025 財年的指導目標設定為每股收益 6.400-6.600 美元。分析師預計 Bristol Myers Squibb Company 在當前年度將發佈每股收益 6.74 美元。</p>
</div><h2>Bristol Myers Squibb Increases Dividend</h2>
<div class="lb-trans"><h2>Bristol Myers Squibb 增加股息</h2>
</div><p>The business also recently announced a quarterly dividend, which will be paid on Monday, February 2nd. Stockholders of record on Friday, January 2nd will be given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.6%. The ex-dividend date is Friday, January 2nd. This is a positive change from Bristol Myers Squibb's previous quarterly dividend of $0.62. Bristol Myers Squibb's dividend payout ratio is currently 83.78%.</p>
<div class="lb-trans"><p>該公司還最近宣佈了一項季度股息，將於 2 月 2 日（星期一）支付。1 月 2 日（星期五）登記的股東將獲得每股 0.63 美元的股息。這相當於每年 2.52 美元的股息和 4.6% 的股息收益率。除息日期為 1 月 2 日（星期五）。這比 Bristol Myers Squibb 之前的季度股息 0.62 美元有所增加。Bristol Myers Squibb 的股息支付比率目前為 83.78%。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新的價格目標</h2>
</div><ul>
<li>MarketBeat Week in Review – 02/03 - 02/07</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 週迴顧 – 02/03 - 02/07</li>
</ul>
</div><p>A number of research analysts recently weighed in on the company. Sanford C. Bernstein reissued a &#34;market perform&#34; rating on shares of Bristol Myers Squibb in a report on Monday, November 3rd. Wall Street Zen upgraded shares of Bristol Myers Squibb from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a report on Saturday, November 8th. Guggenheim restated a &#34;buy&#34; rating on shares of Bristol Myers Squibb in a research note on Tuesday. Weiss Ratings reaffirmed a &#34;hold (c-)&#34; rating on shares of Bristol Myers Squibb in a report on Tuesday, October 14th. Finally, BMO Capital Markets reissued a &#34;market perform&#34; rating on shares of Bristol Myers Squibb in a report on Monday, November 17th. Six equities research analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of &#34;Hold&#34; and an average target price of $54.62.</p>
<div class="lb-trans"><p>一些研究分析師最近對該公司發表了看法。Sanford C. Bernstein 在 11 月 3 日（星期一）的一份報告中重申了對 Bristol Myers Squibb 股票的 “市場表現” 評級。華爾街 Zen 在 11 月 8 日（星期六）的一份報告中將 Bristol Myers Squibb 的股票評級從 “買入” 上調至 “強力買入”。Guggenheim 在週二的一份研究報告中重申了對 Bristol Myers Squibb 股票的 “買入” 評級。Weiss Ratings 在 10 月 14 日（星期二）的一份報告中重申了對 Bristol Myers Squibb 股票的 “持有（C-）” 評級。最後，BMO Capital Markets 在 11 月 17 日（星期一）的一份報告中重申了對 Bristol Myers Squibb 股票的 “市場表現” 評級。六位股票研究分析師對該股票給予了買入評級，十四位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com，該公司目前的平均評級為 “持有”，平均目標價格為 54.62 美元。</p>
</div><p><strong>Read Our Latest Stock Report on Bristol Myers Squibb</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 Bristol Myers Squibb 的最新股票報告</strong></p>
</div><h2>Bristol Myers Squibb Company Profile</h2>
<div class="lb-trans"><h2>Bristol Myers Squibb 公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.</p>
<div class="lb-trans"><p>Bristol Myers Squibb 是一家全球生物製藥公司，總部位於新澤西州普林斯頓，專注於發現、開發和提供針對嚴重疾病的藥物。該公司的核心業務包括研究與開發、臨牀開發、製造和商業化多種治療領域的處方藥。BMS 專注於通過小分子和生物製劑推進腫瘤學、血液學、免疫學、心血管疾病和特殊領域的治療。</p>
</div><p>BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.</p>
<div class="lb-trans"><p>BMS 的市場產品組合和後期管線反映了對癌症和免疫介導疾病的強烈關注。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Bristol Myers Squibb</li>
<li>Turn your &#34;dead money&#34; into $306+ monthly (starting this month)</li>
<li>Washington prepares for war</li>
<li>Put $1,000 into this stock by Jan 1 [Not NVDA]</li>
<li>The McDonald's Secret</li>
<li>33,000% boom from weird new “AI Fuel?”</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票超過 Bristol Myers Squibb</li>
<li>將你的 “死錢” 轉變為每月 306 美元以上（從這個月開始）</li>
<li>華盛頓準備戰爭</li>
<li>在 1 月 1 日之前將 1,000 美元投入這隻股票【不是 NVDA】</li>
<li>麥當勞的秘密</li>
<li>來自奇怪的新 “AI 燃料” 的 33,000% 繁榮？</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding BMY?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對沖基金持有的 BMY 股票嗎？</strong> 訪問 HoldingsChannel.com 獲取 Bristol Myers Squibb Company（紐約證券交易所代碼：BMY - 免費報告）的最新 13F 文件和內部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=BMY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Bristol Myers Squibb Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在百時美施貴寶嗎？</h2>
</div><p>Before you consider Bristol Myers Squibb, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮百時美施貴寶之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bristol Myers Squibb wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而百時美施貴寶並不在名單上。</p>
</div><p>While Bristol Myers Squibb currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然百時美施貴寶目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Donald L. Hagan LLC 購買了 20,550 股百時美施貴寶公司（Bristol Myers Squibb）的股票